Valley Regional Hospital
Kentville, Nova Scotia, B4N 5E3, Canada
Location status: Recruiting
Location contact
Daniel H Affiliated Scientist (Research), PhD
CONTACT
Daniel H Blustein, PhD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT06864741
The goal of this clinical trial is to test whether a low-cost virtual reality (VR) motor rehabilitation platform can improve motor recovery in people recovering from a first-time ischemic stroke both in the hospital and at home. The study focuses on adults aged 18 and older who have experienced moderate to severe upper limb motor deficits.
The main questions it aims to answer are:
* Can VR-based motor therapy improve upper limb motor function compared to standard care? * Is VR-based motor therapy a feasible and acceptable treatment option for stroke patients?
Researchers will compare patients receiving VR therapy to those receiving standard care to see if the VR therapy leads to greater improvements in motor recovery and more positive patient experiences.
Participants will:
* Complete standardized assessments of motor function and quality of life at multiple time points. * Participate in VR therapy sessions (if in the treatment group), using gamified activities designed to improve upper limb movement. * Provide feedback on their experience with the VR system, including ease of use, motion sickness, and engagement.
This study will help determine whether VR-based rehabilitation can be a practical, effective way to improve access to therapy and recovery outcomes for stroke patients, especially in rural settings with limited rehabilitation resources.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Kentville, Nova Scotia, B4N 5E3, Canada
Location status: Recruiting
Daniel H Affiliated Scientist (Research), PhD
CONTACT
Daniel H Blustein, PhD
PRINCIPAL_INVESTIGATOR
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Custom rehabilitation exercises running on a Meta Quest 2/3S/3 head mounted virtual reality display.
Time frame: From enrollment to one week following the end of treatment at day 26
Measure if patients receiving supplementary VR motor therapy show improved motor recovery compared to receiving standard care in hospital using the Fugl-Meyer Assessment's Upper Limb Extremity Subscore. Values range from 0 to 66 with lower scores indicating a larger motor deficit.
Time frame: From enrollment through standard of care and VR treatment completion on Day 47
Measure if patients receiving supplementary VR motor therapy show improved motor recovery compared to receiving standard care for home-based patients using the Fugl-Meyer Assessment's Upper Limb Extremity Subscore. Values range from 0 to 100 with lower scores indicating a larger motor deficit.
Time frame: From enrollment to one week following the end of treatment
Measure motion sickness levels immediately after each therapy sessions using the Virtual Reality Sickness Questionnaire. Values range from 0 to 100 with higher scores indicating more reported motion sickness.
Time frame: From enrollment to one week following the end of treatment
Measure attitudes towards the VR technology before and after the intervention using a VR Attitudes Survey. Values range from 0 to 6 with higher scores indicating more favorable attitudes towards the VR technology.
Time frame: From enrollment through standard of care and VR treatment completion on Day 47
Assess patient engagement with adaptive at-home rehabilitation using the percentage of daily sessions completed. Values range from 0% to 100% with higher scores indicating a higher rate of session completion.
Time frame: From enrollment to one week following the end of treatment
Measure if patients receiving VR motor therapy show improved motor performance using the Box and Blocks Test. Values range from 0 to 150 with higher scores indicating improved motor performance.
Time frame: From enrollment to one week following the end of treatment
Measure if patients receiving VR motor therapy show reduced disability and improved health-related quality of life using the Stroke Impact Scale. Values range from 0 to 100 with higher scores indicating reduced disability and higher quality of life.
Time frame: From enrollment to one week following the end of treatment
Examine the validity of a VR motor assessment for monitoring stroke motor recovery trajectories in the real world. This will be explored by comparing data between the real-world and virtual Box and Blocks tests which will result in a correlation coefficient ranging from 0 to 1 with a higher value indicating a stronger alignment in metrics.
Time frame: From enrollment to one week following the end of treatment
Analyze differences between women and men in relation to the acceptance of VR treatment, using the VR Attitudes Survey. Values range from 0 to 6 with higher scores indicating more favorable attitudes towards the VR technology.
Time frame: From enrollment through standard of care and VR treatment completion on Day 47
By meeting certain criteria during the study, participants can qualify to complete VR sessions on their own. Measure the proportion of participants qualifying for independent operation.
Time frame: From enrollment to last VR rehabilitation session
Measure motor performance for each task over time using motor performance z-scores. Mean scores equal zero with deviations indicating distance in standard deviations from the mean (with no minimum or maximum). Higher scores indicate better motor performance.
Time frame: From enrollment to one week following the last VR session
Qualitative feedback will be analyzed thematically to identify potential barriers and enablers of adopting VR stroke rehabilitation. This qualitative analysis does not use a quantitative scale.
Nova Scotia Health Authority
Other
Acute Stroke Rehabilitation Using a Low-cost Virtual Reality Platform: a Pilot Study.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06315192
Arrhythmias, Cardiac, Atrial Fibrillation
Gothenburg, Sweden
View Trial DetailsNCT07609966
Brain Diseases, Cardiovascular Diseases
Girona, Spain
View Trial DetailsNCT07247669
Brain Diseases, Cardiac Arrest (CA)
Málaga, Spain
View Trial DetailsNCT06975696
Brain Diseases, Cardiovascular Diseases
Helsinki, Finland
View Trial Details